Desidustat vs Molidustat
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: HIF prolyl hydroxylase (HIF-PH1/2/3) · full Chronic Kidney Disease pipeline
Desidustat · Oxemia
Marketed by Zydus Lifesciences and partners
NCT04012957 · Phase 3 · completed
The study was randomized and used an active darbepoetin comparator, but it was open-label and its primary outcome was change in hemoglobin, a surrogate laboratory measure rather than a hard clinical or endoscopic outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
Hemoglobin level (24 weeks): Change in hemoglobin baseline to week 16-24: desidustat +0.95 g/dL vs epoetin alfa +0.80 g/dL (difference 0.14 g/dL, 95% CI -0.13 to 0.42), met prespecified noninferiority margin; hemoglobin responders 59.22% desidustat vs 48.37% epoetin alfa (p=0.0382) (met)
Result source: NCT04215120
Molidustat
Marketed by Bayer
NCT03543657 · Phase 3 · completed
The trial randomized 229 participants to molidustat or darbepoetin alfa with matching placebos and quadruple blinding. Its primary endpoints were hemoglobin measures, which are laboratory surrogate outcomes. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
The mean Hb level during the evaluation period (From week 33 to 36); The change in mean Hb level during the evaluation period from baseline (Baseline and week 33 to 36): Mean Hb during evaluation period (weeks 33-36): molidustat 10.63 g/dL (95% CI 10.42-10.84) vs darbepoetin alfa 10.77 g/dL (95% CI 10.59-10.95); LS mean difference -0.13 g/dL (95% CI -0.46 to 0.19); noninferiority (margin 1.0 g/dL) established (met)
Result source: NCT03543657
Results for Chronic Kidney Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | Desidustat | Molidustat |
|---|---|---|
| Kidney composite outcome | —Not posted · NCT04012957 | —Not posted · NCT03350347 |
| UACR, % change | —Not posted · NCT04012957 | —Not posted · NCT03350347 |
| eGFR slope | —Not posted · NCT04012957 | —Not posted · NCT03350347 |
| Haemoglobin, change | 1.9 vs 1.8avs darbepoetinNCT040129571 other result
| —Not posted · NCT03350347 |
Kidney composite outcome
- Desidustat
- —Not posted · NCT04012957
- Molidustat
- —Not posted · NCT03350347
UACR, % change
- Desidustat
- —Not posted · NCT04012957
- Molidustat
- —Not posted · NCT03350347
eGFR slope
- Desidustat
- —Not posted · NCT04012957
- Molidustat
- —Not posted · NCT03350347
Haemoglobin, change
- Desidustat
- 1.9 vs 1.8avs darbepoetinNCT04012957
1 other result
- 0.9 vs 0.8 NCT04215120
- Molidustat
- —Not posted · NCT03350347
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Desidustat
show 1 more result
show 1 more result
Molidustat
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Desidustat's landscape · Molidustat's landscape